2. Search Result
Search Result
Results for "

antibiotic resistance

" in MedChemExpress (MCE) Product Catalog:

40

Inhibitors & Agonists

1

Screening Libraries

9

Peptides

5

Natural
Products

3

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-106681
    Lagosin

    Fungichromin; Pentamycin; Cogomycin

    		 Antibiotic Fungal Cancer
    Lagosin (Fungichromin) is a polyene macrolide antibiotic. Lagosin has demonstrated broad-spectrum antifungal activity and is impervious to agent resistance .
    Lagosin
  • HY-77641
    Cinnamoylglycine

    		Endogenous Metabolite Metabolic Disease
    Cinnamoylglycine is a glycine conjugate of cinnamic acid and a urinary metabolite in human. Cinnamoylglycine is used as a potential urinary biomarker indicating intact or disrupted colonization resistance during and after antibiotic treatment .
    Cinnamoylglycine
  • HY-146199
    Antibacterial agent 108

    		Bacterial Infection
    Antibacterial agent 108 (Compound 1h) is a potent antibacterial agent with a MIC of both 3 μM against MRSA and antibiotic resistance strains .
    Antibacterial agent 108
  • HY-155504
    Metallo-β-lactamase-IN-11

    		Beta-lactamase Bacterial Infection
    Metallo-β-lactamase-IN-11 (compound 5f) is a Metallo-β-lactamases (MBLs) inhibitor, potent against bacterial metallophyllactamase CphA (IC50=45 µM). Metallo-β-lactamase-IN-11 (10 µM) inhibits NDM-1 by 49% and AIM-1 by 61%. Metallo-β-lactamase-IN-11 can be used in the research of inhibiting antibiotic resistance .
    Metallo-β-lactamase-IN-11
  • HY-P10027
    Clovibactin

    		Antibiotic Bacterial Infection
    Clovibactin is an antibiotic for drug-resistant bacterial pathogens without detectable resistance. Clovibactin TFA inihibits cell wall synthesis by targeting pyrophosphate of peptidoglycan precursors .
    Clovibactin
  • HY-W062216
    2-Aminoimidazole

    		Bacterial Arginase Infection
    2-Aminoimidazole is a potent antibiofilm agent that can be used as an adjuvant to antimicrobial. 2-aminoimidazoles disrupts the ability of bacteria to protect themselves by inhibiting biofilm formation and genetically-encoded antibiotic resistance traits. 2-Aminoimidazole is also a weak noncompetitive inhibitor of human arginase I with a Ki of 3.6 mM .
    2-Aminoimidazole
  • HY-P1674A
    Murepavadin TFA
    2 Publications Verification

    POL7080 TFA

    		 Bacterial Antibiotic Infection
    Murepavadin (POL7080) (TFA), a 14-amino-acid cyclic peptide, is a highly potent, specific antibiotic. Murepavadin exhibits a potent antimicrobial activity for P. aeruginosa with MIC50 and MIC90 values both of 0.12 mg/L. Murepavadin also can target the lipopolysaccharide transport portin D. Murepavadin can be used for the research of bacterial resistance .
    Murepavadin TFA
  • HY-P1674
    Murepavadin

    POL7080

    		 Bacterial Antibiotic Infection
    Murepavadin (POL7080), a 14-amino-acid cyclic peptide, is a highly potent, specific antibiotic. Murepavadin exhibits a potent antimicrobial activity for P. aeruginosa with both MIC50 and MIC90 values of 0.12 mg/L. Murepavadin also can target the lipopolysaccharide transport portin D. Murepavadin can be used for the research of bacterial resistance .
    Murepavadin
  • HY-P10211
    Virgilagicin

    		Antibiotic Bacterial Infection
    Virgilagicin is a Gram-positive active antibiotic that has a dual polyprenyl phosphate binding mechanism that impedes resistance development .
    Virgilagicin
  • HY-P10209
    Cilagicin

    		Antibiotic Bacterial Infection
    Cilagicin, a dodeca-lipodepsipeptide, is a Gram-positive active antibiotic. Cilagicin has a dual polyprenyl phosphate binding mechanism that impedes resistance development .
    Cilagicin
  • HY-B1329
    Apramycin sulfate
    2 Publications Verification

    Nebramycin II sulfate

    		 Bacterial Antibiotic Infection
    Apramycin (EBL 1003) is an orally active, acidic pH tolerant and aminoglycoside-modifying-enzymes-tolerant aminoglycoside antibiotic which inhibits protein biosynthesis by targeting the bacterial ribosome. Apramycin is a potential anti-drug-resistance antibiotic .
    Apramycin sulfate
  • HY-126906
    Milbemycin A4

    		Antibiotic P-glycoprotein Cancer
    Milbemycin A4 inhibits P-glycoprotein activity, and reverses multidrug resistance of tumor cells. Milbemycins are a family of macrolide antibiotics with insecticidal and acaricidal activity sup>[2].
    Milbemycin A4
  • HY-N9386
    Tellimagrandin II
    1 Publications Verification

    Eugeniin

    		 Bacterial Antibiotic Infection Inflammation/Immunology
    Tellimagrandin II (Eugeniin), the first intermediate in the 4C1-glucose derived series of ellagitannins, also inhibits antibiotic resistance of drug-resistant Staphylococcus aureus .
    Tellimagrandin II
  • HY-100589
    Isepamicin sulfate

    Sch 21420 sulfate
    Isepamicin sulfate (Sch 21420 sulfate) is a broad spectrum aminoglycoside antibiotic. Isepamicin sulfate exhibits considerable antimicrobial activity against Gram-negative non-fermenters in a region with high antimicrobial resistance .
    Isepamicin sulfate
  • HY-P5620
    DFTamP1

    		Bacterial Infection
    DFTamP1 is an antimicrobial peptide against Staphylococcus aureus USA300 activity (MIC is 3.1 μM) .
    DFTamP1
  • HY-P10210
    Paenilagicin

    		Antibiotic Bacterial Infection
    Paenilagicin is a Gram-positive active antibiotic with a unique diphosphorylated prenyl binding mechanism that does not induce drug resistance. Paenilagicin exhibits a MIC value of 2 μg/mL against multidrug-resistant Gram-positive bacteria .
    Paenilagicin
  • HY-77641S
    Cinnamoylglycine-d2

    		Endogenous Metabolite Metabolic Disease
    Cinnamoylglycine-d2 is the deuterium labeled Cinnamoylglycine. Cinnamoylglycine is a glycine conjugate of cinnamic acid and a urinary metabolite in human. Cinnamoylglycine is used as a potential urinary biomarker indicating intact or disrupted colonization resistance during and after antibiotic treatment[1].
    Cinnamoylglycine-d2
  • HY-P10027A
    Clovibactin TFA

    		Antibiotic Bacterial Infection
    Clovibactin TFA is the TFA salt form of Clovibactin (HY-P10027). Clovibactin TFA is an antibiotic for drug-resistant bacterial pathogens without detectable resistance. Clovibactin TFA inihibits cell wall synthesis by targeting pyrophosphate of peptidoglycan precursors .
    Clovibactin TFA
  • HY-149333
    BO-1

    		Bacterial Infection
    BO-1 is a benzoate ester with antibacterial activity. BO-1 inhibits multidrug-resistant Staphylococcus aureus, and acts function synergistically with antibiotic, such as Ciprofloxacin (HY-B0356). BO-1 can reverse the resistance of antibiotic-resistant S. aureus strains, and decreases the level of inflammatory factors IL-6 and C-reactive protein in vivo in mice .
    BO-1
  • HY-146330
    FtsZ-IN-2

    		Bacterial Infection
    FtsZ-IN-2 (Compound 19) is an inhibitor of the bacterial cell division protein FtsZ with GTPase inhibitory activity. FtsZ-IN-2 exhibits anti-staphylococcal activity with MIC values of 2 µg/ml for MSSA and MRSA .
    FtsZ-IN-2
  • HY-156414
    DHFR-IN-11

    		Dihydrofolate reductase (DHFR) Infection
    DHFR-IN-11 (compound 6b) is inhibitor of DHFR, and has inhibitory potency versus M. tuberculosis DHFR enzyme with IC50 values 5.70 μM .
    DHFR-IN-11
  • HY-127146
    Platensimycin

    		Antibiotic Bacterial
    Platensimycin is an antibiotic produced by S. platensis that inhibits gram-positive bacteria by selectively inhibiting cellular lipid biosynthesis (IC50=0.1 μM). Platensimycin targets the β-ketoacyl-acyl-carrier-protein synthase I/II, FabF/B, an enzyme that participates in the biosynthesis of fatty acids (IC50s=48 nM and 160 nM for S.aureus and E.coli enzymes, respectively). Platensimycin is a promising agent for overcoming antibiotic resistance.
    Platensimycin
  • HY-146331
    PC190723

    		Bacterial Antibiotic Infection
    PC190723 (Compound 2) is an inhibitor of the bacterial cell division protein FtsZ with an IC50 of 55 ng/ml. FtsZ-IN-3 exhibits anti-staphylococcal activity with MIC values of 1 µg/ml for MSSA and MRSA .
    PC190723
  • HY-B1599
    Chloramphenicol palmitate

    		Bacterial Antibiotic Infection
    Chloramphenicol palmitate is an orally active broad spectrum antibiotic and has a broad spectrum of activity against gram positive and gram negative bacteria. Chloramphenicol palmitate inhibits bacterial protein synthesis by blocking the peptidyl transferase step. Chloramphenicol palmitate can be used as bacterial selection agent in transformed cells containing chloramphenicol resistance genes .
    Chloramphenicol palmitate
  • HY-106668
    Isepamicin

    Sch 21420

    		 Antibiotic Bacterial Infection
    Isepamicin (Sch 21420) is an aminoglycoside antibacterial. Isepamicin has better activity against strains producing type I 6'-acetyltransferase. Isepamicin’s antibacterial spectrum includes Enterobacteriaceae and staphylococci. Anaerobes, Neisseriaceae and streptococci are resistant. Isepamicin exhibits a strong concentration-dependent bactericidal effect, a long post-antibiotic effect (several hours) and induces adaptive resistance .
    Isepamicin
  • HY-B1455
    Clindamycin
    5 Publications Verification
    Clindamycin is an orally active and broad-spectrum bacteriostatic lincosamide antibiotic. Clindamycin can inhibit bacterial protein synthesis, possessing the ability to suppress the expression of virulence factors in Staphylococcus aureus at sub-inhibitory concentrations (sub-MICs). Clindamycin resistance results from enzymatic methylation of the antibiotic binding site in the 50S ribosomal subunit (23S rRNA). Clindamycin decreases the production of Panton-Valentine leucocidin (PVL), toxic-shock-staphylococcal toxin (TSST-1) or alpha-haemolysin (Hla). Clindamycin also can be used for researching malaria .
    Clindamycin
  • HY-B1455S
    Clindamycin-d3 hydrochloride

    		Bacterial Antibiotic Parasite Infection
    Clindamycin-d3 (hydrochloride) is the deuterium labeled Clindamycin. Clindamycin is an orally active and broad-spectrum bacteriostatic lincosamide antibiotic. Clindamycin can inhibit bacterial protein synthesis, possessing the ability to suppress the expression of virulence factors in Staphylococcus aureus at sub-inhibitory concentrations (sub-MICs). Clindamycin resistance results from enzymatic methylation of the antibiotic binding site in the 50S ribosomal subunit (23S rRNA). Clindamycin decreases the production of Panton-Valentine leucocidin (PVL), toxic-shock-staphylococcal toxin (TSST-1) or alpha-haemolysin (Hla). Clindamycin also can be used for researching malaria[1][2].
    Clindamycin-d3 hydrochloride
  • HY-B1599R
    Chloramphenicol palmitate (Standard)

    		Bacterial Antibiotic Infection
    Chloramphenicol palmitate (Standard) is the analytical standard of Chloramphenicol palmitate. This product is intended for research and analytical applications. Chloramphenicol palmitate is an orally active broad spectrum antibiotic and has a broad spectrum of activity against gram positive and gram negative bacteria. Chloramphenicol palmitate inhibits bacterial protein synthesis by blocking the peptidyl transferase step. Chloramphenicol palmitate can be used as bacterial selection agent in transformed cells containing chloramphenicol resistance genes .
    Chloramphenicol palmitate (Standard)
  • HY-116815
    Lalistat 1

    		Beta-lactamase Bacterial Infection Neurological Disease
    Lalistat 1 is a potent, selective, and competitive inhibitor of lysosomal acid lipase (LAL) and against purified human LAL (phLAL) with an IC50 of 68 nM. Lalistat 1 is a inhibitor of immunoglobulin A1 protease (IgA1P) proteases for H. influenzae, has less effects on other serine hydrolases (trypsin or β-lactamase, etc.). Lalistat 1 can be used for the research of niemann-pick type C (NPC) disease .
    Lalistat 1
  • HY-N7118
    Clindamycin hydrochloride monohydrate

    		Bacterial Antibiotic Infection Cancer
    Clindamycin hydrochloride monohydrate is an oral protein synthesis inhibitory agent that has the ability to suppress the expression of virulence factors in Staphylococcus aureus at sub-inhibitory concentrations (sub-MICs). Clindamycin hydrochloride monohydrate resistance results from enzymatic methylation of the antibiotic binding site in the 50S ribosomal subunit (23S rRNA). Clindamycin hydrochloride monohydrate decreases the production of Panton-Valentine leucocidin (PVL), toxic-shock-staphylococcal toxin (TSST-1) or alpha-haemolysin (Hla) .
    Clindamycin hydrochloride monohydrate
  • HY-150766
    KPC-2-IN-1

    		Bacterial Infection
    KPC-2-IN-1, boronic acid derivative, is a potent KPC-2 inhibitor with Ki of 0.032 μM. KPC-2-IN-1 enhances the activity of cefotaxime in KPC-2 expressing E. coli. KPC-2-IN-1 exhibits well tolerated in human HEK-293 cells, which can be used for the study of E. coli resistance to β-lactam antibiotics .
    KPC-2-IN-1
  • HY-162174
    MBL-IN-2

    		Beta-lactamase Bacterial Infection
    MBL-IN-2 ((2R, 2R')-5αC) is an inhibitor of Metallo-β-lactamase (MBL) that can inhibit New Delhi Metallo-β-lactamase-1 (NDM-1) with an IC50 of 0.3 μM. MBL-IN-2 ((2R, 2R')-5αC) can be used for the study of resistance to β-lactam antibiotics .
    MBL-IN-2
  • HY-B1455S1
    Clindamycin-13C,d3

    		Isotope-Labeled Compounds Bacterial Antibiotic Parasite Infection
    Clindamycin- 13C,d3 is the 13C- and deuterium labeled Clindamycin. Clindamycin is an orally active and broad-spectrum bacteriostatic lincosamide antibiotic. Clindamycin can inhibit bacterial protein synthesis, possessing the ability to suppress the expression of virulence factors in Staphylococcus aureus at sub-inhibitory concentrations (sub-MICs). Clindamycin resistance results from enzymatic methylation of the antibiotic binding site in the 50S ribosomal subunit (23S rRNA). Clindamycin decreases the production of Panton-Valentine leucocidin (PVL), toxic-shock-staphylococcal toxin (TSST-1) or alpha-haemolysin (Hla). Clindamycin also can be used for researching malaria[1][2][3].
    Clindamycin-13C,d3
  • HY-P3078
    Amphomycin

    		Bacterial Antibiotic Infection
    Amphomycin is a lipopeptide antibiotic that inhibits peptidoglycan synthesis and blocks cell wall development. Amphomycin exhibits potent antibacterial activities against methicillin-resistant S. aureus (MRSA), vancomycin-resistant enterococci (VRE), penicillin-gentamicin-erythromycin-resistant S. pneumonia, and linezolid-quinupristin-dalfopristin-resistant enterococci .
    Amphomycin
  • HY-144659
    Metallo-β-lactamase-IN-5

    		Beta-lactamase Apoptosis Bacterial Infection
    Metallo-β-lactamase-IN-5 (compound 5c) is a potent metallo-β-lactamases (MBL) inhibitor. Metallo-β-lactamase-IN-5 shows inhibitory activity against MBLs NDM-1 and VIM-1. Metallo-β-lactamase-IN-5 inhibits HUVECs with an IC50 of 45 μg/mL. Metallo-β-lactamase-IN-5 plus Imipenem exhibits synergistic antimicrobial activity .
    Metallo-β-lactamase-IN-5
  • HY-147531
    Antibacterial agent 106

    		Bacterial Infection
    Antibacterial agent 106 (compound 8) is an orally active and potent antibacterial agent with antibiofilm activity. Antibacterial agent 106 shows potent antibacterial effect against multi-agent resistant (MDR)-Gram positive pathogens. Antibacterial agent 106 is highly effective in clearing 99.7% of the intracellular methicillin-resistant S. aureus (MRSA) harbored inside macrophages . Antibacterial agent 106 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Antibacterial agent 106
  • HY-147674
    Isoleucyl tRNA synthetase-IN-2

    		Aminoacyl-tRNA Synthetase Infection
    Isoleucyl tRNA synthetase-IN-2 (compound 36a) is a potent and selective isoleucyl-tRNA synthetase (IleRS) inhibitor, with a Ki,app of 114 nM .
    Isoleucyl tRNA synthetase-IN-2
  • HY-147671
    CB 168

    		Aminoacyl-tRNA Synthetase Infection
    CB 168 is a potent and selective aminoacyl-sulfamoyl aryltetrazole inhibitor targeting isoleucyl-tRNA synthetase (IleRS) .
    CB 168
  • HY-147672
    IleRS-IN-1

    		Aminoacyl-tRNA Synthetase Infection
    IleRS-IN-1 (compound 11) is a potent and selective isoleucyl-tRNA synthetase (IleRS) inhibitor, with a Ki,app of 88 nM .
    IleRS-IN-1
  • HY-103251
    PF-5081090

    LpxC-4

    		 Antibiotic Bacterial Infection
    PF-5081090 (LpxC-4) is a potent LpxC inhibitor, is a rapidly bactericidal with broad-spectrum activity. PF-5081090 serves as a regulator of lipid A biosynthesis in Gram-negative pathogens .
    PF-5081090

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: